Telomir-1 Shows Promise in Treating Aggressive Prostate Cancer by Resetting Key Defense Systems.

Telomir Pharmaceuticals reported new data showing that Telomir-1 resets cancer's "kill-and-clean" defense systems in an aggressive prostate cancer model, outperforming Rapamycin and chemo. The findings highlight Telomir-1's impact on CASP8 and GSTP1, critical genes regulating cell death and glutathione-based detoxification pathways often disrupted in cancer. Telomir-1 treatment was associated with reduced methylation of CASP8 and GSTP1, suggesting potential reactivation of apoptotic and detoxification pathways.